Cargando…

Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells

Receptor tyrosine kinase (RTK) signaling pathways are frequently activated in cancer cells due to mutations of RTKs and/or their downstream signaling proteins such as KRAS and BRAF. About 40% colorectal cancers (CRCs) contain KRAS or BRAF mutant genes and are resistant to treatments with individual...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Qiaoling, Sun, Xiaoxiao, Guo, Hui, Yu, Qiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354887/ https://www.ncbi.nlm.nih.gov/pubmed/28002807 http://dx.doi.org/10.18632/oncotarget.14009

Ejemplares similares

Synergistic blocking of RAS downstream signaling and epigenetic pathway in KRAS mutant pancreatic cancer
por: Zhang, Xiaofei, et al.
Publicado: (2022)

Synergistic Effects of Combined Wnt/KRAS Inhibition in Colorectal Cancer Cells
por: Mologni, Luca, et al.
Publicado: (2012)

Dual inhibition of VEGF and PARP suppresses KRAS-mutant colorectal cancer
por: Zhong, Longhui, et al.
Publicado: (2020)

Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
por: Temraz, Sally, et al.
Publicado: (2015)

Frequency and Clinicopathological Characteristics of Patients With KRAS/BRAF Double-Mutant Colorectal Cancer: An In Silico Study
por: Uchida, Shiro, et al.
Publicado: (2022)

KRAS and BRAF genotyping of synchronous colorectal carcinomas
por: GIANNINI, RICCARDO, et al.
Publicado: (2014)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
por: Paoluzzi, Luca, et al.
Publicado: (2016)

Platycodin D sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the PI3K/Akt signaling pathway
por: Liu, Yanfei, et al.
Publicado: (2022)

Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models
por: Davis, S. Lindsey, et al.
Publicado: (2015)

RUNX2/CBFB modulates the response to MEK inhibitors through activation of receptor tyrosine kinases in KRAS-mutant colorectal cancer
por: Šuštić, Tonći, et al.
Publicado: (2019)

Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers
por: Hata, Aaron N, et al.
Publicado: (2017)

Concomitant Kinase-Dead BRAF and Oncogenic KRAS Lead to an Aggressive Biologic Behavior and Tumor Lysis Syndrome: A Case Report
por: Holland, Roy, et al.
Publicado: (2022)

p53-armed oncolytic adenovirus induces autophagy and apoptosis in KRAS and BRAF-mutant colorectal cancer cells
por: Tamura, Shuta, et al.
Publicado: (2023)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer
por: Hiraki, Masayuki, et al.
Publicado: (2015)

KRAS and BRAF Concomitant Mutations in a Patient with Metastatic Colon Adenocarcinoma: An Interesting Case Report
por: Cafiero, Concetta, et al.
Publicado: (2020)

Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma
por: Stefanius, Karoliina, et al.
Publicado: (2011)

Mitochondrial Respiration in KRAS and BRAF Mutated Colorectal Tumors and Polyps
por: Rebane-Klemm, Egle, et al.
Publicado: (2020)

Ciliated muconodular papillary tumors of the lung with KRAS/BRAF/AKT1 mutation
por: Udo, Emiko, et al.
Publicado: (2017)

The role of RICTOR downstream of receptor tyrosine kinase in cancers
por: Jebali, Ahlem, et al.
Publicado: (2018)

Targeting mutant BRAF in colorectal cancer
por: Carroll, David, et al.
Publicado: (2013)

Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer
por: Wagner, Steve, et al.
Publicado: (2018)

Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
por: Wang, Jieqiong, et al.
Publicado: (2016)

Intermittent BRAF Inhibition Can Achieve Prolonged Disease Control in BRAF Mutant Melanoma
por: Jain, Tania, et al.
Publicado: (2015)

KRAS, NRAS, BRAF, PIK3CA, and AKT1 signatures in colorectal cancer patients in south-eastern Romania
por: Brinzan, Costel Stelian, et al.
Publicado: (2022)

A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification
por: Dugo, Matteo, et al.
Publicado: (2015)

Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?
por: Yokota, Tomoya
Publicado: (2012)

Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer
por: Ntavatzikos, Anastasios, et al.
Publicado: (2017)

BRAF Inhibition in BRAF(V600)-Mutant Gliomas: Results From the VE-BASKET Study
por: Kaley, Thomas, et al.
Publicado: (2018)

BRAF-Mutant Pulmonary Langerhans Cell Histiocytosis Mimicking Recurrence of Early-Stage KRAS-Mutant Lung Adenocarcinoma
por: Alden, Stephanie L., et al.
Publicado: (2020)

Characteristics of and Treatment Strategies for Advanced EGFR-Mutant NSCLC With Concomitant BRAF Variations
por: Wei, Xue-Wu, et al.
Publicado: (2022)

Correction: Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer
por: Wagner, Steve, et al.
Publicado: (2019)

Dual inhibition of CDK4 and FYN leads to selective cell death in KRAS-mutant colorectal cancer
por: Wang, Yan, et al.
Publicado: (2019)

AIM2 Inhibits BRAF-Mutant Colorectal Cancer Growth in a Caspase-1-Dependent Manner
por: Shah, Shailendra, et al.
Publicado: (2021)

Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation
por: Byeon, Hyung Kwon, et al.
Publicado: (2016)

KRAS mutant colorectal tumors: Past and present
por: Brand, Toni M., et al.
Publicado: (2012)

AKT2 Loss Impairs BRAF-Mutant Melanoma Metastasis
por: McRee, Siobhan K., et al.
Publicado: (2023)

KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer
por: Nakayama, N, et al.
Publicado: (2008)

Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer
por: Choughule, A, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_712o3duhk692u928gctibofb5g